Symptom Burden and Survivorship Care for Patients With Prostate Cancer on Androgen Deprivation Therapy

被引:0
|
作者
Sentana-Lledo, Daniel [1 ]
Saraf, Anurag [2 ,3 ]
Morgans, Alicia K. [1 ]
机构
[1] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA
[3] Brigham & Womens Hosp, Boston, MA USA
关键词
CARDIOVASCULAR-DISEASE; COGNITIVE FUNCTION; RADIATION-THERAPY; AMERICAN-SOCIETY; HORMONAL-THERAPY; BONE HEALTH; MEN; RISK; TESTOSTERONE; BICALUTAMIDE;
D O I
10.6004/jnccn.2024.7047
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer survivors represent a growing population of patients with a diagnosis of prostate cancer, whether they were cured using local therapies or continue to receive systemic treatment of advanced disease. Many patients receive androgen deprivation therapy (ADT) during treatment, which is associated with many long-lasting physical and psychological effects. Identifying and addressing the needs of survivors is imperative for improving their health and well-being. This narrative review highlights the most common issues associated with ADT affecting survivorship in prostate cancer, including cardiovascular and metabolic effects, musculoskeletal health, sexual morbidity, and local therapy effects, as well as the mental and psychological toll. A special emphasis is placed on the existing literature examining specific interventions to alleviate these symptoms, along with describing existing gaps in knowledge, with the goal of promoting dedicated studies aimed at enhancing the survivorship experience of patients with prostate cancer.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Androgen Deprivation Therapy and Prostate Cancer Duration
    Williams, Scott G.
    Pickles, Tom
    Buyyounouski, Mark K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : E228 - E228
  • [42] Intermittent androgen deprivation therapy for prostate cancer
    Rashid, MH
    Chaudhary, UB
    ONCOLOGIST, 2004, 9 (03): : 295 - 301
  • [43] Androgen deprivation therapy for early prostate cancer
    Tanday, Sanjay
    LANCET ONCOLOGY, 2014, 15 (06): : E199 - E199
  • [44] Prostate cancer, insulin, and androgen deprivation therapy
    P Stattin
    R Kaaks
    British Journal of Cancer, 2003, 89 : 1814 - 1815
  • [45] Complications of androgen deprivation therapy in prostate cancer
    Schwandt, Anita
    Garcia, Jorge A.
    CURRENT OPINION IN UROLOGY, 2009, 19 (03) : 322 - 326
  • [46] Complications of androgen deprivation therapy for prostate cancer
    Holzbeierlein, JM
    McLaughlin, MD
    Thrasher, JB
    CURRENT OPINION IN UROLOGY, 2004, 14 (03) : 177 - 183
  • [47] Androgen deprivation therapy for prostate cancer: An overview
    Rabbani, F
    Fair, WR
    INFECTIONS IN UROLOGY, 1999, 12 (03): : 69 - 74
  • [48] Advances with androgen deprivation therapy for prostate cancer
    Yu, Eun-mi
    Aragon-Ching, Jeanny B.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (09) : 1015 - 1033
  • [49] Androgen and prostate cancer: the role of primary androgen deprivation therapy in localized prostate cancer
    Namiki, Mikio
    Kitagawa, Yasuhide
    Mizokami, Atsushi
    Koh, Eitetsu
    JOURNAL OF MENS HEALTH, 2008, 5 (04) : 333 - 341
  • [50] Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
    Klotz, L.
    Toren, P.
    CURRENT ONCOLOGY, 2012, 19 : S13 - S21